|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia. |
| 公司地址
| 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660 |
| 電話號碼
| +1 949 284-4555 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.evolus.com |
| 員工數量
| 334 |
| Ms. Tatjana Mitchell |
Chief Financial Officer and Principal Accounting Officer |
美元 154.22K |
29/04/2026 |
| Mr. David Moatazedi |
Director, President and Chief Executive Officer |
美元 775.00K |
29/04/2026 |
| Dr. Rui Avelar, M.D. |
Head of Research and Development and Chief Medical Officer |
美元 545.40K |
29/04/2026 |
|
|
| Ms. Karah Parschauer, J.D. |
Independent Director |
29/04/2026 |
| Ms. Brady Stewart |
Independent Director |
29/04/2026 |
| Mr. Albert G. White, III |
Independent Director |
29/04/2026 |
| Mr. Vikram Malik |
Chairman of the Board |
29/04/2026 |
| Mr. David Moatazedi |
Director, President and Chief Executive Officer |
29/04/2026 |
| Mr. David N. Gill |
Independent Director |
29/04/2026 |
|
|
|
|
